4//SEC Filing
Liau Gene 4
Accession 0001209191-20-055378
CIK 0001623526other
Filed
Oct 19, 8:00 PM ET
Accepted
Oct 20, 4:52 PM ET
Size
21.2 KB
Accession
0001209191-20-055378
Insider Transaction Report
Form 4
Liau Gene
EVP Research & Preclinical Dev
Transactions
- Exercise/Conversion
Common Stock
2020-10-16$0.60/sh+5,851$3,511→ 19,351 total - Exercise/Conversion
Common Stock
2020-10-19$0.60/sh+30,497$18,298→ 43,997 total - Sale
Common Stock
2020-10-19$38.42/sh−7,225$277,586→ 13,500 total - Sale
Common Stock
2020-10-16$40.00/sh−5,851$234,042→ 13,500 total - Exercise/Conversion
Common Stock
2020-10-19$2.19/sh+1,503$3,292→ 45,500 total - Sale
Common Stock
2020-10-19$37.64/sh−24,775$932,578→ 20,725 total - Exercise/Conversion
Employee Stock Option (right to buy)
2020-10-19−30,497→ 96,069 totalExercise: $0.60Exp: 2028-04-02→ Common Stock (30,497 underlying) - Exercise/Conversion
Employee Stock Option (right to buy)
2020-10-19−1,503→ 70,386 totalExercise: $2.19Exp: 2028-12-12→ Common Stock (1,503 underlying) - Exercise/Conversion
Employee Stock Option (right to buy)
2020-10-16−5,851→ 126,566 totalExercise: $0.60Exp: 2028-04-02→ Common Stock (5,851 underlying)
Footnotes (6)
- [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.02 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.18 to $38.10 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.19 to $38.90 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The option vested as to 1/4th of the total shares on January 16, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.
- [F6]The option vested as to 3/48th of the total shares on January 22, 2019, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.
Documents
Issuer
Stoke Therapeutics, Inc.
CIK 0001623526
Entity typeother
Related Parties
1- filerCIK 0001780082
Filing Metadata
- Form type
- 4
- Filed
- Oct 19, 8:00 PM ET
- Accepted
- Oct 20, 4:52 PM ET
- Size
- 21.2 KB